Newsletter | August 1, 2008

8.1.08 -- Telik's TRAP Drug Discovery Technology Surpasses 3 Million Molecular Fingerprint Milestone

www.drugdiscoveryonline.com
This Newsletter Is Sponsored By:
Allow your team to work when and where they need to on American's most reliable wireless broadband network.   With BroadbandAccess Built-In your mobile workforce can rely on the authentication and data protection of CDMA technology, which provides a greater level of security than Wi-Fi. Visit here for more information.
Top News Stories
Telik's TRAP Drug Discovery Technology Surpasses 3 Million Molecular Fingerprint Milestone
Telik, Inc. announced recently that its library of diverse profiled compounds now exceeds 3.3 million. The expanded library significantly enhances Telik's patented drug discovery technology, Target Related Affinity Profiling (TRAP)...

Ikaria Receives Fda Orphan Drug Designation For Inhaled Carbon Monoxide For Delayed Graft Function In Solid Organ Transplants
Ikaria Holdings, Inc., a fully integrated critical care biotherapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for inhaled carbon monoxide for use in the reduction of the incidence and severity of delayed graft function (DGF) in patients undergoing solid organ transplantation...

Lorus Therapeutics Announces Allowance Of New United States Patent For Its Anticancer Drug LOR-2040
Lorus Therapeutics Inc. ("Lorus"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, recently announced the allowance of a new patent from the United States Patent and Trademark Office for its clinical-stage anticancer drug LOR-2040...

Infinity Announces Conference Call Discussing R&D Progress And Second Quarter 2008 Results
Infinity Pharmaceuticals, Inc. , an innovative cancer drug discovery and development company, today announced that Infinity management will host a conference call on Monday, August 4, 2008 at 4:30 p.m. EDT. In the conference call, management will provide a research and development update and discuss results for the quarter ended June 30, 2008...

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application To FDA For Rivaroxaban
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that it has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for rivaroxaban...

Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation For Parkinson's Research Award For Work On PD-implicated Protein LRRK2
Zenobia Therapeutics, Inc. (Zenobia) announced recently that it has received a Therapeutics Development Initiative award from The Michael J. Fox Foundation for Parkinson's Research. The program targets industry-based research with potential to fundamentally alter the course of Parkinson's disease (PD) treatment...

PTC Therapeutics Honored For Patient Advocacy Efforts By The Genetic Alliance
PTC Therapeutics, Inc. (PTC) recently announced that the company was awarded the Art of Industry Partnership Award by the Genetic Alliance. Genetic Alliance presents the Art of Listening, Art of Advocacy, and Art of Industry Partnership Awards annually...

A High-Density Lipoprotein Raising Drug That Has A Lower Discontinuation Rate Than That Of Extended Release Niaspan Would Earn A 20 Percent Patient Share In The Dyslipidemia Drug Market
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug that raises high-density lipoprotein cholesterol and has a lower discontinuation rate than that of Abbott's Niaspan ER (extended release) would earn a 20 percent patient share in the treatment of dyslipidemia, according to surveyed endocrinologists...

Unique Drug Monitoring Site eHealthMe Opens Its Doors To Visitors
People on medication are to benefit from a new website where they can find out if the drugs they are taking are safe to use initially, and if they are safe to mix with other medicine...

Featured Products
Software For Signal Analysis And Processing: AutoSignal®
AutoSignal is the first and only program that completely automates the process of analyzing signals. Save precious time by eliminating the programming time normally required for performing sophisticated signal analysis...

Chromatography
Pall's chromatography systems cover a full range of applications with the highest consistency in design principles and operating protocols. Pall meets its customers needs with both standardized and fully customized products, and offers comprehensive local support wherever the location...

Subscriber Services
• Forward to a colleague
• Add us to your safe senders list
• Update preferences
• Unsubscribe
Featured Downloads
Technical Journal: GeneDex: A Journal Dedicated To Innovative Technologies For Gene Function Discovery
In the latest GENEDEX, Editor Michele Nealen focuses on ExactORF custom cloning service. OriGene will deliver the sequence-verified open reading frame of your choice, in the vector of your choice. You're not limited to human and mouse sequences; they'll produce an ExactORF clone from any species you need...
Datasheet: ULT Series Recirculating Chiller
ULT recirculating chillers from FTS Systems offer heat removal rates for reaction vessel cooling up to 3 times higher than other brands for almost half the price...
Profile Update Prize
Update your contact information and be entered to win an Apple iPhone.
Newsletter Subscription
If you do not currently receive the Drug Discovery Online newsletter and wish to become a subscriber, click here.
Advertise Online
If you are interested in advertising with Drug Discovery Online, click here for more information.

©Copyright VertMarkets LLC, 101 Gibraltar Road, Suite 100, Horsham, PA 19044. All rights reserved. All product names contained herein are the trademarks of their respective holders.